Type ? Target Frizzled receptor ATC code none | Source Human Routes of
administration IV CAS Number 1345009-45-1 | |
Vantictumab /vænˈtɪktᵿmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029.
It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.
References
Vantictumab Wikipedia(Text) CC BY-SA